Conciseness

The body is dense operational instruction with no concept padding, but contains noticeable redundancy: the 'Sample Triggers' section repeats the four input examples verbatim, Step 3's config-table requirements are restated nearly word-for-word in Section B, and Hard Rules 3/14, 12/15, and 13/6 overlap substantially. This fits 'mostly efficient but could be tightened' rather than the 4 anchor's 'minor instances'.

Actionability

Guidance is concrete throughout: exact valid-input grammar, a pattern-selection table, named workload configs with defined fields, an exact out-of-scope redirect to quote, exact disclaimer line, and per-section output specifications with example formats (dependency map, reference-pack categories). Below 5 because several executable details live only in references (the 8-field step template, figure/deliverable plan — Section E is a bare link), leaving minor gaps in the body itself.

Workflow Clarity

Seven steps 'always run in order' with explicit validation checkpoints and a feedback loop: input validation with a stop-and-redirect rule, the mandatory Step 5 dependency consistency check with 'If any dependency inconsistency is found, revise the plan before outputting', the mandatory Step 4.5 citation-verification rules with fallback behavior when browsing is unavailable, and a 15-item hard-rules checklist. This matches the 5 anchor's clear sequence, explicit validation, and error-recovery loop.

Progressive Disclosure

The body is a well-organized overview with clearly signaled, one-level-deep references ('→ Detailed pattern logic: [references/study-patterns.md]', etc.); all 8 referenced files exist in the bundle with substantive content (41–137 lines each), and no reference chains further into other files, matching the 5 anchor exactly.

Specificity

The description lists several concrete methodological actions — 'using active comparators, disproportionality analysis, subgroup characterization' — grounded in a named domain (FAERS pharmacovigilance study design for 'multi-drug or class-level safety comparison inside one predefined SOC or AE family'). It falls short of the 5 anchor because 'Generates complete... study designs' and 'reviewer-facing evidence control' are mildly padded/over-claiming, while sitting above the 3 anchor by naming more than 1-2 concrete actions.

Completeness

The 'what' is clear (generates FAERS comparative study designs with named methods), but there is no 'Use when...' clause or equivalent explicit trigger guidance — per the judging guidelines this caps completeness at 3. Not 2 because the 'what' is specific and detailed, not vague.

Trigger Term Quality

Strong natural domain keywords users would say: 'FAERS', 'pharmacovigilance', 'safety comparison', 'SOC', 'active comparators', 'disproportionality analysis'. Below 5 because common user phrasings like 'adverse event' (only the abbreviation 'AE' appears), 'signal detection', or 'post-marketing surveillance' are missing.

Distinctiveness Conflict Risk

A clear niche is stated ('multi-drug or class-level safety comparison inside one predefined SOC or AE family' with 'active comparators'), which distinguishes it from generic document or data skills. Below 5 because it belongs to an apparent family of similar FAERS/pharmacovigilance planner skills (whole-profile single-drug designs, etc.), leaving minor overlap risk with closely related siblings.